Download PDF
psychoneuro 2008; 34(4): 184-189
DOI: 10.1055/s-2008-1079314
Schwerpunkt

© Georg Thieme Verlag Stuttgart · New York

Pharmakotherapie der Schizophrenie - Leitliniengerecht und individuell

Pharmacological treatment of schizophrenia - After guidelines and individuallyThomas Wobrock1 , Oliver Gruber1
  • 1Zentrum für Psychosoziale Medizin, Abt. für Psychiatrie und Psychotherapie, Georg-August-Universität Göttingen(Direktor: Prof. Dr. P. Falkai)
Further Information

Publication History

Publication Date:
09 May 2008 (online)

    Permissions and Reprints

Antipsychotika haben sich in der medikamentösen Behandlung der Schizophrenie sowohl in der Akutphase als auch in der Langzeitbehandlung als wirksam erwiesen. Mit der Einführung der Antipsychotika der 2. (und 3.) Generation („Atypika”) stehen dem Behandler differenzierte Therapieoptionen hinsichtlich eines günstigeren Nutzen-Risiko-Verhältnisses zur Verfügung. In der vorliegenden Übersicht werden die empfohlenen medikamentösen Behandlungsstrategien in den einzelnen Krankheitsphasen dargelegt und auf der Basis der vorhandenen Evidenz kritisch diskutiert.

Antipsychotics have proven efficacy in the acute phase and long-term pharmacotherapy of schizophrenia. With the introduction of second (and third) generation antipsychotics differential treatment options and an improved risk-benefit ratio become available. In the review the recommended treatment strategies in the different phases of the disease are presented and discussed on the background of evidence-based medicine.

Key words

Schizophrenia - pharmacotherapy - antipsychotics - long-term treatment

Literatur

  • 1 Adams CE, Fenton MK, Quraishi S, David AS.. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia.  Br J Psychiatry. 2001;  179 290-299
    CrossrefPubMedSearch in Google Scholar
  • 2 Andreasen NC, Carpenter Jr WT, Kane JM. et al. . Remission in schizophrenia: proposed criteria and rationale for consensus.  Am J Psychiatry. 2005;  162 441-449
    CrossrefPubMedSearch in Google Scholar
  • 3 Baumann P, Hiemke C, Ulrich S. et al. . The AGNP-TDM expert group consensus guidlines: therapeutic drug monitoring in psychiatry.  Pharmacopsychiatry. 2004;  37 243-265
    Thieme ConnectPubMedSearch in Google Scholar
  • 4 Correll CU, Leucht S, Kane JM.. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.  Am J Psychiatry. 2004;  161 414-425
    CrossrefPubMedSearch in Google Scholar
  • 5 Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) (Hrsg.). .S3-Praxisleitlinien Psychiatrie und Psychotherapie. Band 1. Behandlungsleitlinie Schizophrenie. Leitlinienprojektgruppe: Gaebel W, Falkai P, Weinmann S, Wobrock T. Darmstadt: Steinkopff-Verlag 2006
    Search in Google Scholar
  • 6 Falkai P, Wobrock T, Lieberman J. et al. . World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.  World J Biol Psychiatry. 2005;  6 132-191
    Search in Google Scholar
  • 7 Falkai P, Wobrock T, Lieberman J. et al. . World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia.  World J Biol Psychiatry. 2006;  7 5-40
    CrossrefPubMedSearch in Google Scholar
  • 8 Gaebel W, Riesbeck M, Wölwer W. et al. . Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia. One-year results of a randomized controlled trial within the German Research Network on Schizophrenia.  J Clin Psychiatry. 2007;  69 1763-1774
    PubMedSearch in Google Scholar
  • 9 Harvey PD, Keefe RSE.. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.  Am J Psychiatry. 2001;  158 176-184
    Search in Google Scholar
  • 10 Kissling W. Guidelines for neuroleptic relapse prevention in schizophrenia. Heidelberg: Springer-Verlag 1991
    Search in Google Scholar
  • 11 Kohen D.. Diabetes mellitus and schizophrenia: historical perspective.  Br J Psychiatry Suppl. 2004;  184
    PubMedSearch in Google Scholar
  • 12 Lasser RA, Bossie CA, Gharabawi GM, Kane JM.. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection.  Schizophr Res. 2005;  77 215-227
    CrossrefPubMedSearch in Google Scholar
  • 13 Lehman AF, Lieberman JA, Dixon LB. et al. . Practice guideline for the treatment of patients with schizophrenia, second edition.  Am J Psychiatry. 2004;  161 1-56
    Search in Google Scholar
  • 14 Leucht S, Barnes TR, Kissling W. et al. . Relapse pevention in shizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.  Am J Psychiatry. 2003;  160 1209-1222
    Search in Google Scholar
  • 15 Loo H, Poirier-Littre MF, Theron M. et al. . Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia.  Br J Psychiatry. 1997;  170 18-22
    PubMedSearch in Google Scholar
  • 16 McGorry P, Killackey E, Elkins K. et al. . Summary Australian and New Zealand clinical practice guideline for the treatment of schizophrenia.  Australasian Psychiatry. 2003;  11 136-147
    CrossrefPubMedSearch in Google Scholar
  • 17 Mishara AL, Goldberg TE.. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book.  Biol Psychiatry. 2004;  55 1013-1022
    Search in Google Scholar
  • 18 Möller HJ.. Management of the negative symptoms of schizophrenia. New treatment options.  CNS Drugs. 2003;  17 793-823
    CrossrefPubMedSearch in Google Scholar
  • 19 Möller HJ.. Non-neuroleptic approaches to treating negative symptoms in schizophrenia.  Eur Arch Psychiatry Clin Neurosci. 2004;  254 108-116
    CrossrefPubMedSearch in Google Scholar
  • 20 National Institute for Clinical Excellence. .Core Interventions in the Treatment of Schizophrenia. NICE, London, 2003. www.nice.org.uk
  • 21 Robinson DG, Woerner MG, McMeniman M. et al. . Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder.  Am J Psychiatry. 2004;  161 473-479
    CrossrefPubMedSearch in Google Scholar
  • 22 Rummel C, Kissling W, Leucht S.. Antidepressants for the negative symptoms of schizophrenia.  Cochrane Database Syst Rev. 2006;  3
    PubMedSearch in Google Scholar
  • 23 Schooler N, Rabinowitz J, Davidson M. et al. . Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.  Am J Psychiatry. 2005;  162 947-953
    Search in Google Scholar
  • 24 Wobrock T, Falkai P.. Leitliniengestützte Therapie schizophrener Psychosen.  INFO Neurologie & Psychiatrie. 2003;  5 34-45
    PubMedSearch in Google Scholar
  • 25 Wobrock T, Falkai P.. Medikamentöse Langzeittherapie zur Symptomsuppression bei chronisch Schizophrenen. In: Möller HJ (Hrsg.). Therapie psychischer Erkrankungen. Teil II, Behandlung spezieller Erkrankungen, Schizophrene Erkrankungen. 3. vollständig überarbeitete Auflage, Stuttgart: Thieme-Verlag 2006: 274-290
    Search in Google Scholar

Korrespondenz

Dr. med. Thomas Wobrock

Zentrum für Psycho-soziale Medizin Abteilung für Psychiatrie und Psychotherapie Georg-August-Universität Göttingen

Von-Siebold-Straße 5

37075 Göttingen